Navigation

mechlorethamine topical (Valchlor)

 

Classes: Dermatologics, Other; Antineoplastics, Alkylating

Dosing and uses of Valchlor (mechlorethamine topical)

 

Adult dosage forms and strengths

topical geL

  • 0.016% (equivalent to 0.02% mechlorethamine HCl)

 

Cutaneous T-Cell Lymphoma

Indicated for stage 1A and 1B mycosis fungoides-type cutaneous T-cell lymphoma in patients who have received prior skin-directed therapy

Apply a thin film of gel topically to affected areas of the skin once daily

 

Dosage modifications

Skin toxicities

  • Stop treatment for any grade of skin ulceration, blistering, or moderately‐severe or severe dermatitis (ie, marked skin redness with edema)
  • Upon improvement, may resume at reduced application frequency of once q3days
  • After 1 week at q3days, may increase frequency to every other day for at least 1 week, and then to once daily if tolerated

 

Administration

Apply immediately or within 30 minutes after removal from the refrigerator; return gel to the refrigerator immediately after each use

Apply to completely dry skin at least 4 hr before or 30 minutes after showering or washing

Allow treated areas to dry for 5-10 minutes after application before covering with clothing

Emollients (moisturizers) may be applied to the treated areas 2 hr before or 2 hr after application

Do not use occlusive dressings on areas of the skin where gel applied

Avoid fire, flame, and smoking until the gel has dried

Storage

  • Before dispensing, store in freezer (‐13-5°F (‐25°C to ‐15°C)
  • Following dispensing, instruct patient that gel requires refrigeration

Cytotoxic handling

  • Cytotoxic drug; follow applicable special handling and disposal procedures
  • Patients must wash hands thoroughly with soap and water after handling or applying
  • Caregivers must wear disposable nitrile gloves when applying gel to patients and wash hands thoroughly with soap and water after removal of gloves
  • If there is accidental skin exposure, caregivers must immediately wash exposed areas thoroughly with soap and water for at least 15 minutes and remove contaminated clothing

 

Pediatric dosage forms and strengths

Safety and efficacy not established

 

Valchlor (mechlorethamine topical) adverse (side) effects

>10%

Dermatitis, any grade (56%)

Dermatitis, moderately-severe or severe (23%)

Pruritus, any grade (20%)

Bacterial skin infection, any grade (11%)

 

1-10%

Skin ulceration or blistering (3-6%)

Skin hyperpigmentation (5%)

Pruritus, moderately-severe or severe (4%)

Bacterial skin infection, moderately-severe or severe (2%)

 

Warnings

Contraindications

Hypersensitivity

 

Cautions

Avoid eye exposure; may cause pain, burns, inflammation, photophobia, and blurred vision; blindness and severe irreversible anterior eye injury may occur Avoid direct skin contact with individuals other than the patient; risk of secondary exposure include dermatitis, mucosal injury, and secondary cancers

Dermatitis occurs commonly (see Adverse effects); modify dose if skin toxicity occurs (see Dosage modifications)

Nonmelanoma skin cancer reported

Based on its mechanism of action, case reports in humans, and findings in animals, mechlorethamine topical can cause fetal harm when administered pregnant women

Alcohol-based gels are flammable

 

Pregnancy and lactation

Pregnancy category: D; case reports of children born with malformations in pregnant women systemically administered mechlorethamine

Mechlorethamine was teratogenic in animals after a single SC administration

Lactation: Unknown if distributed in human breast milk; a decision should be made whether to discontinue nursing or the drug, taking into account the importance of the drug to the mother

 

Pregnancy categories

A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

NA: Information not available.

 

Pharmacology of Valchlor (mechlorethamine topical)

Mechanism of action

Alkylating agent which inhibits rapidly proliferating cells

Also known as nitrogen mustard

 

Absorption

Systemic exposure was undetectable after topical administration